BioSpace News Archive

Dyne Therapeutics , Inc . (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management will present at upcoming virtual investor conferences. Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, will participate in fireside chats at the following: Stifel 20

Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that the first patient has been treated with NTLA-2001, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR). Intellia’s global Phase 1 study is to eva

Intra-Cellular Therapies today announced its financial results for the third quarter ended September 30, 2020, and provided a corporate update.

Wave Life Sciences today announced financial results for the third quarter ended September 30, 2020 and provided a business update.

Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for Vicineum TM in December 2020 Manufacturing of Vicineum drug substance and drug product PPQ batches has been completed Emerging manufacturing data provides strong support for analytical comparability between clinical and commercial material

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) – November 13-16, 2020 Title: ARO-AAT Reduces Serum and Intra-hepatic Z-AAT Protein in PIZZ Alpha-1 Antitrypsin Deficient Patients with Liver Disease Lead

Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced the closing of a new $150 million senior secured revolving credit facility with JPMorgan Chase Bank, N.A. as administrative agent and a syndicate of three relationship banks.

TELA Bio, Inc. announced that it will be featured on The Balancing Act to increase patient awareness of mesh options for hernia repair, including its next-generation soft-tissue repair solution, OviTex.

Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, highlights a series of clinical case reports and animal studies presented in abstract and poster formats at the 2020 Symposium on Advanced Wound Care (SAWC) Fall, which took place from November 4-6, 2020. The conference was hosted online due to the pandemic. Terrence W. Norchi, MD, President and CEO of Arch

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Cowen 2020 IO Next Summit on Friday, November 13, 2020 at 12:15 p.m. ET.